Search results
Results from the WOW.Com Content Network
Novavax successfully developed a COVID-19 vaccine that is currently its only product on the market. The company has been working on two other candidates. One is an investigational influenza vaccine.
Shares of vaccine stocks Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and BioNTech SE (NASDAQ: BNTX) rallied this week, appreciating 23.4%, 16.4%, and 9.3%, respectively, through Thursday ...
COVID-19 vaccines gave Moderna, Pfizer and Johnson & Johnson a boost — but are the stocks still a good investment in 2021? Here's what to consider before buying in.
In this article we will take a look at the 10 best vaccine stocks to buy now. You can skip our comprehensive analysis of the biopharma industry and go directly to the 5 Best Vaccine Stocks to Buy ...
Kennedy has long railed against vaccines, once calling those that protect against Covid-19 a "crime against humanity." He has treaded more carefully in recent weeks, though, and has said he wouldn ...
Over the past year, Pfizer stock has dipped 11%, and Moderna stock has plunged 46%. ... thanks largely to its Comirnaty Covid-19 vaccine and Paxlovid antiviral pill – the boom subsided by early ...
The news got even better last week, when the UK drug regulatory commission MHRA authorized Pfizer and BioNTech to distribute their Covid-19 mRNA vaccine for emergency use and the first doses could ...
The company — which expects its 2023 revenus to be at least $6 billion — reported $1.8 billion in COVID-19 vaccine sales in the third quarter and $3.9 billion through Q3.